16 participants
A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Previously Received BCG
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2007-01-29
- Start Date:
- 2003-05-31
Conditions
- Tuberculosis
Interventions
- BIOLOGICAL
No Results Yet